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INJECTING CAUTION: A NEED FOR ENHANCED 
STATE-LEVEL ENFORCEMENT TACTICS 
TARGETING THE COSMETIC USE OF LIQUID 
SILICONE PRODUCTS 
Katherine Cohen Cooper* 
INTRODUCTION 
Liquid silicone, first developed commercially for the purposes of 
insulating electrical transformers, gained popularity in the United States 
during the second half of the twentieth century as a cosmetic injection.1  
Although the United States Food and Drug Administration (“FDA”) has 
never approved liquid silicone for cosmetic uses, physicians have injected 
the substance in patients’ breasts, bodies, and faces for cosmetic 
enhancement since the 1950s.2  In more recent years, as record numbers of 
patients seek out minimally invasive cosmetic procedures such as 
injectables, illicit liquid silicone injections have been on the rise.3  Often, 
patients hoping to obtain quick cosmetic results turn to unlicensed 
professionals to administer liquid silicone injections, or receive injections of 
adulterated or industrial-grade silicone.4  While these cosmetic interventions 
can be easy to obtain and cost thousands of dollars less than a similar 
procedure performed by a licensed physician, these conveniences all too 
frequently come at the expense of patient health and safety.5 
The following article provides a background of the development of liquid 
silicone as a tool for cosmetic enhancement, as well as a brief overview of 	  
* J.D., Harvard Law School, 2013; B.A., Duke University, 2007. 
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Say, USA TODAY (Oct. 28, 2011, 2:42 PM), http://usatoday30.usatoday.com/new/health/ 
story/health/story/2011-10-29/illegal-silicone-buttock-injections-can-be-deadly-experts-
say/50978858/1. 
 4. Angela Esther Kim, “Wine, Cheese and a Dash of Poison in the Forehead:” 
Exploring the Evolution of the Injectable Filler Industry and the Consequent Implications 
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the historical regulatory approach toward controlling cosmetic uses of these 
products.  The article goes on to describe the current legal status of liquid 
silicone injections, as well as the scope of its current uses.  It also examines 
various legal and regulatory mechanisms that have been offered as means to 
control illicit uses of liquid silicone injections.  Given the barriers towards 
achieving effective federal regulation and control of illicit liquid silicone 
injections, as evidenced through descriptions of the current and historical 
regulatory regimes, this article concludes that state-level regulation and 
enforcement will be the most practical route for controlling unsafe and 
illegal cosmetic liquid silicone procedures.  As such, this article advocates 
for a selection of promising state-level legal reforms targeting both 
physicians and unlicensed individuals that seek to provide patients with 
injections of liquid silicone. 
I. THE DEVELOPMENT OF LIQUID SILICONE INJECTIONS 
The scientific term for liquid silicone is dimethylpolysiloxane fluid.6  The 
silicones are a family of chemically related substances comprised of silicon 
atoms bonded to oxygen and carbon atoms; silicone polymers range in 
viscosity from fluids to solids.7  Although the term “silicone” has become 
synonymous with cosmetic uses, the substance was first developed for 
industrial purposes.  During World War II, the United States military used 
liquid silicone to insulate electrical transformers.8  Also during this era, 
however, U.S. troops stationed in Japan began to notice that drums of 
transformer insulating fluid were being stolen from docks in Japanese 
harbors.  It became evident that this silicone fluid was being injected into the 
breasts of Asian prostitutes who sought a more Western appearance to cater 
to the American servicemen.9  Silicone breast injections migrated to 
America in the 1950s when Asians who practiced the procedure immigrated.  
Initially, silicone breast injections were black market procedures, most 
commonly administered to women who worked in the entertainment 
industry.10  During the 1950s and early 1960s, transformer fluid made by 
Dow Corning (“Dow”) was the only liquid silicone product on the market; 	  
 6. Rhoda S. Narins & Kenneth Beer, Liquid Injectable Silicone: A Review of Its 
History, Immunology, Technical Considerations, Complications, and Potential, 118 
PLASTIC & RECONSTRUCTIVE SURGERY J. 77S, 78S (2006). 
 7. R.R. LeVier, M.C. Harrison, R.R. Cook, & T.H. Lane, What is Silicone?, 92 
PLASTIC & RECONSTRUCTIVE SURGERY J. 163 (Jul. 1993); see also M. Sharon Webb, 
Cleopatra’s Needle: The History and Legacy of Silicone Injections, 2 (Jan. 1997) 
(unpublished course paper) (on file with Harvard Law School). 
 8. Hilts, supra, note 1. 
 9. Id. 
 10. Foreman, supra note 2.  
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thus, throughout this time period, only this industrial-grade material was 
used in these cosmetic procedures.11 
As time passed, liquid silicone injections became more mainstream.  One 
physician in Las Vegas was quoted in a 1963 Newsweek article claiming to 
have injected 16,000 doses of silicone into the breasts of over 200 women.12  
As the popularity of silicone injections grew, reports of adverse events 
associated with these procedures also became more prevalent.  For example, 
clinicians began to note that liquid silicone injected in the breasts tended to 
migrate to adjacent areas and form irregular subcutaneous masses.13  To 
address this issue, a Beverly Hills physician named Dr. Sakurai popularized 
a version of the liquid silicone formula that contained inflammatory agents.14 
These new agents produced scarring around the injection area, and when 
added to the liquid silicone, helped the silicone fluid to remain immobilized 
in the desired region.15  Because these adulterants caused separate problems 
in patients, Dow developed and marketed a medical grade liquid silicone, 
intended for use in clinical experimentation.16 
In large part, Dow developed medical grade silicone because the company 
had become aware that physicians were putting liquid silicone to wide use.  
Capitalizing on the market potential of medical uses for liquid silicone, Dow 
established a medical products business division in 1962.17  Along with this 
new endeavor came oversight from the FDA.  As Dow assumed its new role 
as a medical products company, the company instituted efforts to avoid 
misuse of medical grade liquid silicone by its customers.  Purchasers of its 
Medical 360 fluid were required to sign an affidavit stating that the material 
would only be used for lubrication purposes.18  Despite this effort, however, 	  
 11. E. L. WARRICK, FORTY YEARS OF FIRSTS 169 (1990). 
 12. Paul E. Chasan, The History of Injectable Silicone Fluids for Soft Tissue 
Augmentation, 120 PLASTIC & RECONSTRUCTIVE SURGERY J. 7, 2034, 2035 (Dec. 2007); 
see also Webb, supra note 7, at 11.  
 13. See, e.g., N. Ben-Hur, D.L. Ballantyne, T.D. Rees,  & I. Seidman, Local and 
Systemic Effects of Dimethylpolysiloxane Fluid in Mice, 39 PLASTIC & RECONSTRUCTIVE 
SURGERY J.  423 (1967). 
 14. Chasan, supra note 12, at 2035.  
 15. Is the FDA Protecting Patients from the Dangers of Silicone Breast Implants?: 
Hearing before the Human Resources and Intergovernmental Relations Subcommittee of 
the Committee on Government Operations, 101st Cong. 30 (Dec. 18 1990) (statement of 
Norman D. Anderson, M.D., Associate Professor of Medicine and Surgery, Johns 
Hopkins University School of Medicine, and Former Chairman, General and Plastic 
Surgery Devices Advisory Panel, FDA). 
 16. F. McDowell, Complications with Silicone: What Grade of Silicone? How Do 
We Know it Was Silicone?, 61 PLASTIC & RECONSTRUCTIVE SURGERY J. 892 (June 1978). 
 17. DOW CORNING CORP., HIGHLIGHTS FROM THE HISTORY OF DOW CORNING 
CORPORATION, SILICONE PIONEER, http://www.dowcorning.com/content/publishedlit/01-
4027-01.pdf. 
 18. See Webb, supra note 7, at 16-18. 
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the FDA declared Medical 360 fluid to be a new drug in 1964, requiring the 
substance to adhere to the Food, Drug and Cosmetic Act (“FDCA”) and 
submit a successful New Drug Application (“NDA”).19 
II. HISTORICAL REGULATION OF MEDICAL-GRADE LIQUID SILICONE 
A. FDA Initially Classifies Liquid Silicone as a “Drug” 
In response to the FDA’s classification of Medical 360 fluid as a drug, 
Dow assembled a panel of scientific experts to begin conducting animal 
studies involving liquid silicone.  These experts were quickly convinced of 
liquid silicone’s safety, and began to test the fluid in human patients.20  The 
FDA permitted Dow to begin Phase II human subject trials in 1965, but 
these studies were replete with design flaws.21  Having failed to amass 
sufficient safety and effectiveness data by 1976, Dow withdrew the Medical 
360 NDA and deferred its attempt to gain FDA approval for its liquid 
silicone product.  In 1977, Dow submitted an amended protocol for clinical 
trials of Medical 360 fluid.22  Noting that Dow’s animal studies had been 
plagued with inconsistencies, the FDA explicitly required that liquid silicone 
trials only be used for serious facial deformities; cosmetic applications were 
not allowed as part of these new clinical trial protocols.23  As a result, 
responsibility for liquid silicone as a transitional medical device was given 
to the Bureau of Devices and given a new investigational device exemption 
number (“IDE”).24 
B. Liquid Silicone is Re-Classified as a “Device” But Does Not Receive Pre-
Market Approval 
As these renewed clinical trials were underway, the 1976 Medical Device 
Amendments to the FDCA went into effect.  These amendments charged the 
FDA with identifying drugs that should be re-classified as devices; silicone 
	  
 19. Id. 
 20. F.L. Ashley, S. Braley, & E.G. McNall, The Current Status of Silicone Injection 
Therapy, 51 SURGICAL CLINICS N. AM. 501 (1971). 
 21. Id.  Particularly troubling, it was found that silicone fluid tended to disappear 
from the injection site.  However, none of the researchers could determine where this 
silicone had migrated. 
 22. Chasan, supra note 12. 
 23. See Promotion of Drugs and Medical Devices for Unapproved uses: Hearing 
before the H. Comm. of Human Res. and Intergovernmental Relations Subcomm. of the 
Comm. on Gov’t Operations, 102nd Cong., (207-208) (June 11, 1991) (Memorandum 
from Paul F. Tilton to The Record, September 10 , 1990). 
 24. Id. at 208. 
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injections were deemed a device in 1977.25  Subsequently, Dow researchers 
continued clinical trials of silicone injections in patients with severe 
deformities as investigational medical device trials.26  In 1988, the FDA 
ruled that silicone injections should be considered Class III medical devices, 
requiring that the devices obtain pre-market approval (“PMA”) from the 
agency.27  As Dow gathered data for the PMA application, the FDA 
requested an interim report, which the company filed in 1990.  The agency 
deemed the submitted material unsatisfactory, citing the dearth of long-term 
follow-up with study patients, insufficient pre- and post-treatment lab 
studies, no objective measures of improvement, and inadequate 
demonstrations of individual patient results.28  Dow did not correct these 
deficiencies in its data, nor did it file a formal PMA application or submit 
further safety and efficacy information.  Thus, the IDE that had allowed 
Dow to continue clinical trials of the Medical 360 device permanently 
expired in January 1992; the product was subsequently retired from clinical 
medicine.29 
C. Despite Lack of Pre-Market Approval, FDA Enforcement Against 
Cosmetic Silicone Injections Is Weak 
By 1992, the FDA had never approved liquid silicone injections as either 
a drug or device.30  Nevertheless, silicone fluid was widely used within the 
United States medical community at this time.31  Particularly popular was 
the use of liquid silicone to cosmetically shape the face.32  While the FDA 
occasionally issued rulings reflecting its approbation of silicone injections, 
the agency generally exhibited ambivalence towards regulating liquid 
silicone.33  For example, the FDA became aware that Dr. Norman 
Orentreich, one of the investigators permitted to conduct liquid silicone trials 
under Dow’s Medical 360 IDE, was injecting silicone fluid into patients for 
reasons outside the scope of addressing serious facial deformities, as was 
	  
 25. JUDITH JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF MEDICAL 
DEVICES 5 (June 25, 2012). 
 26. See Webb, supra note 7, at 29. 
 27. Regulatory History of Breast Implants in the U.S., FOOD & DRUG ADMIN.,  
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthe
tics/BreastImplants/ucm064461.htm (last visited May 12, 2014). 
 28. See Webb, supra note 7, at 30. 
 29. See id. at 31. 
 30. Webb, supra note 7, at 30 (stating that the IDE for silicone injections “became 
invalid in January, 1992”).  
 31. Kim, supra note 4, at 25. 
 32. Id. at 24. 
 33. HR. REP. NO. 102-1064, at 3 (1992). 
254 The Journal of Contemporary Health Law and Policy Vol. XXX:2 
specified in the IDE protocol.34  While the FDA did respond by dropping 
Orentreich from the roster of approved investigators, he nevertheless 
continued to maintain “a robust cosmetic practice as a dermatologist in New 
York City, with appreciative movie stars as patients.”35  In the face of this 
defiance, the FDA warned Orentreich about his continued cosmetic usage of 
liquid silicone and called for an injunction in 1985.36  Ultimately, however, 
Orentreich was permitted to continue his practice, and the injunction 
recommendation was placed in permanent abeyance.37   As justification for 
this inaction, the agency noted its reluctance “to single out one physician 
when illegal use of liquid silicone was widespread,” and further that issues 
related to the practice of medicine were best addressed at the state level.38  
As cosmetic use of liquid silicone became increasingly widespread without 
firm regulatory guidance from FDA, the Department of Justice stepped in 
and began filing injunctions on behalf of the agency to prohibit physicians 
from injecting silicone fluid in patients.39  In the early 1990s, the 
Department of Justice filed its own injunction against Dr. Orentreich.40  By 
1992, the FDA had followed suit, entering consent decrees of permanent 
injunction against several additional physicians.41 
D. States Attempt to Regulate Liquid Silicone in the Face of FDA Inaction 
Although the FDA’s efforts to curb illegal silicone injections were limited 
between 1964 and 1992, many states were more active in combating such 
activity during this timeframe.42  As data in the medical literature and in 
clinical practice regarding adverse effects of liquid silicone injections began 
to accumulate, so too did political attention throughout many regions of the 
country.43  In Nevada, a Las Vegas plastic surgeon alerted the state’s 
attorney general to the dangers of these procedures and the health risks it 
caused for the city’s entertainers.44  In 1975, Nevada passed a law 
criminalizing silicone injections.45  States such as California soon followed 	  
 34. Webb, supra note 7, at 32. 
 35. Id. 32-33. 
 36. Id. at 34. 
 37. Id. 
 38. Id. at 33. 
 39. Press Release, Food and Drug Admin., Physicians to Stop Injecting Silicone for 
Cosmetic Treatment of Wrinkles (Feb. 28, 1992), available at 
http://www3.scienceblog.com/community/older/archives/M/1/fda0893.htm. 
 40. Kim, supra note 4, at 24. 
 41. Judith E. Foulke, Two Doctors Ordered to Stop Silicone Injections, FDA 
CONSUMER, Mar. 1993, at 27. 
 42. Webb, supra note 7, at 23-24. 
 43. Id. at 24. 
 44. Foreman, supra note 2. 
 45. Id. 
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suit, beginning to prosecute doctors for violating these laws.46  Medical 
malpractice suits and criminal cases brought in state courts were also 
successfully used to punish and hold responsible physicians and other 
individuals who harmed patients with liquid silicone injections.  In People v. 
Ellison, for example, the defendant was convicted of involuntary 
manslaughter for recklessly injecting silicone into a transgender woman.47  
The principal factual issue at trial was whether the silicone injection caused 
the victim’s death.48  On appeal, the court held that the victim’s death was 
caused by the silicone injection because expert testimony concluded that the 
cause of death was suffocation resulting from the presence of silicone 
vacuoles in the victim’s lungs.49 
III. CURRENT LEGAL AND REGULATORY STATUS OF LIQUID SILICONE 
A. FDA Approval of Medical Devices Generally 
Under Section 513(a) of the FDCA, the FDA determines whether 
Premarket Approval (“PMA”) applications provide a “reasonable assurance 
of [a device’s] safety and effectiveness” by “weighing any probable benefit 
to health from the use of the device against any probable risk of injury or 
illness from such use.”50  To aid in this process, PMA applicants submit 
valid scientific evidence, including one or more clinical investigations where 
appropriate, which FDA reviews to determine whether the device will have 
the effect it purports or is represented to have under the conditions of use 
prescribed, recommended, or suggested in the labeling of the device.51  
Medical devices can be evaluated using clinical and non-clinical testing 
methods.52  FDA assesses information provided in a PMA application 
concerning the extent of probable benefits of the device by taking into 
account factors such as the types of benefits involved, the magnitude of the 
benefits, the probability of the patient experiencing one or more benefits, 
and the duration of the effects.53  These benefits are balanced against the 	  
 46. NEV. REV. STAT. § 202.248 (1995); CAL. BUS. & PROF. CODE § 2251 (West 
1980); see also Nelson v. Gault, 125 Cal. App. 3d 623, 639-40 (Cal. Ct. App. 1981) 
(holding that physician’s testimony that he was aware that silicone was considered illegal 
and that he was arrested for injecting it without a permit was admissible to prove 
knowledge of the falsity of the representation made to patient that silicone was inert and 
harmless). 
 47. People v. Ellison, 100 Ill. App. 3d 282, 283 (1981). 
 48. Id. 
 49. Id. at 290. 
 50. 21 U.S.C.  § 360(a)(2)(C) (2010). 
 51. Id. 
 52. Id. 
 53. Id. 
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probable risks and harms associated with the device, including the severity 
and rates of harmful events associated with the use of the device, the 
probability of a harmful event, and the duration of a harmful event.54  
Additionally, FDA will consider factors such as uncertainty, characterization 
of the condition, patient tolerance for risk, availability of alternative 
treatments, and novelty of the technology in conducting a benefit-risk 
determination.55 
In the context of FDA approval for cosmetic or anti-aging devices, 
measuring efficacy and comparing risks and benefits can be complicated.56  
As an initial matter, “it is unclear what endpoints the [FDA] should require 
manufacturers to use in order to prove efficacy.57  Additionally, it may be 
difficult to identify the “symptoms” associated with aging or with cosmetic 
problems, as well as to determine what qualifies as relief of those 
“symptoms.”58  Nevertheless, FDA does approve many drugs and devices 
for cosmetic indications, such as nonprescription contact lenses, breast 
implants, and Botox.59  For example, in seeking approval of Botox cosmetic, 
Allergan, the product’s manufacturer, conducted studies with co-primary 
efficacy endpoints of the Investigator’s rating of glabellar line severity at 
maximum frown at Day 30 after injection and the Subject’s Global 
Assessment of change in appearance in glabellar lines at Day 30 after 
injection.60  By the primary efficacy endpoint day, Day 30, 80% of subjects 
had achieved a severity score of none or mild at maximum frown by the 
investigator’s assessment, compared to 3% of placebo treated patients.61  On 
the other hand, the most frequently reported adverse events following 
injection of Botox Cosmetic were relatively minor, including headache, 	  
 54.  Id. 
 55. See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUM. SERVS., GUIDANCE 
FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF: FACTORS TO CONSIDER 
WHEN MAKING BENEFIT-RISK DETERMINATIONS IN MEDICAL DEVICE PREMARKET 
APPROVAL AND DE NOVO CLASSIFICATIONS (Mar. 28, 2012), http://www.fda.gov/ 
downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM2
96379.pdf.  
 56. Maxwell J. Mehlman, et al., Anti-Aging Medicine: Can Consumers be Better 
Protected?, 44 GERONTOLOGIST 304, 306 (2004). 
 57. Id. 
 58. Id.  
 59. Id. at 307. 
 60. FOOD & DRUG ADMIN, U.S. DEP’T OF HEALTH & HUM. SERVS., APPROVAL 
RECOMMENDATION FOR STN 100300/5000 SUBMITTED BY ALLERGAN, INC. TO USE 
BOTULINUM TOXIN TYPE A (BOTOX COSMETIC) FOR TREATMENT OF GLABELLAR FACIAL 
LINES (Apr. 12, 2002), http://www.fda.gov/downloads/Drugs/ DevelopmentApproval 
Process/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologi
cApplications/ucm088280.pdf [hereinafter FDA, BOTOX COSMETIC APPROVAL]. 
 61. Id. 
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respiratory infection, flu, and nausea.62  Based on an analysis of these 
results, the FDA approved Botox Cosmetic for the temporary reduction in 
the appearance of moderate to severe glabellar lines in 2002.63 
B. Legal “Off-Label” Uses of Approved Liquid Silicone Products 
While liquid silicone has never received FDA approval for cosmetic use, 
certain liquid silicone products were approved by the agency as medical 
devices between 1994 and 1997.  Section 201(h) of the FDCA defines 
“device” as follows: 
The term “device” . . . means an instrument, apparatus, implement, 
machine, contrivance, implant, in vitro reagent, or other similar or 
related article, including any component, part, or accessory, which 
is . . . intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or prevention of 
disease, in man or other animals, or intended to affect the structure 
or any function of the body of man or other animals, and which 
does not achieve its primary intended purposes through chemical 
action within or on the body of man or other animals and which is 
not dependent upon being metabolized for the achievement of its 
primary intended purposes.64 
Presently two liquid silicone devices have received pre-market approval 
from the FDA: Adatosil 5000 and Silikon 1000; these devices are approved 
for the treatment of complicated retinal detachments.65  Pursuant to this 
approved indication, these liquid silicone products are temporarily injected 
into the eye to hold the retina in place while it heals.66  FDA approval of 
these liquid silicone products has opened the door for the legal 
administration of liquid silicone injections for cosmetic treatment.  This 
legal but unapproved indication is known as an “off-label use.”67 	  
 62. Id. 
 63. Id. 
 64. 21 U.S.C. §321(h) (2010).  It is important to note that the definition of a medical 
device includes any article that is “intended to affect the structure or any function of the 
body.”  Therefore, a product intended for cosmetic use and designed to beautify or 
promote attractiveness can nevertheless be classified as a medical device by the FDA, 
regardless of whether the device is intended to be used for reconstructive or solely 
cosmetic purposes. 
 65. Erin Gilbert, Andrea Hui, & Heidi A. Waldorf, The Basic Science of Dermal 
Fillers: Past and Present: Part I: Background and Mechanisms of Action, 11 J. DRUGS 
DERMATOLOGY 1064 (2012). 
 66. Vitreoretinal Surgery: ADATO Sil-O-Silicone Oil, BAUSCH & LOMB, 
http://www.bausch.com/en/ECP/Our-Products/Vitreoretinal-Surgery/ADATO-Sil-Ol-
Silicone-Oil (last visited Apr. 10, 2013). 
 67. “Off-label” and Investigational Use of Marketed Drugs, Biologics, and Medical 
Devices–Information Sheet, FOOD & DRUG ADMIN., 
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FDA defines off-label use as use for an “indication, dosage, form, dose 
regimen, population or other use parameter not mentioned in the approved 
labeling” of a drug or device.68  While off-label use of drugs has long been 
authorized by the FDA, Congress more recently extended the same 
endorsement of off-label use to devices when it passed the Food and Drug 
Administration Modernization Act (“FDAMA”) in 1997.69  The FDAMA 
states that the Act must not “limit or interfere with the authority of a health 
care practitioner to prescribe or administer any legally marketed device to a 
patient for any condition or disease within a legitimate health care 
practitioner-patient relationship.”70  FDA maintains this general policy of 
non-interference with the practice of medicine because “off-label uses or 
treatment regimens may be important therapeutic options and may even 
constitute a medically recognized standard of care.”71  Given the importance 
of off-label uses in many circumstances, the agency merely constrains off-
label use by physicians by admonishing that physicians using “a product for 
an indication not in the approved labeling . . . have the responsibility to be 
well informed about the product, to base its use on firm scientific rationale 
and on sound medical evidence, and to maintain records of the product’s use 
and effects.”72  Essentially, the regulatory status of off-label use and 
prescribing of drugs and devices represents a conscious choice by Congress 
to prevent the FDA from regulating the physician-patient relationship, 
limited only by Congressional recognition of “a patient’s right to seek civil 
damages in the courts if there should be evidence of malpractice.”73  Given 
such leeway in the practice of medicine, off-label prescribing by physicians 
is widespread.  An estimated 25% to 60% of all prescriptions are for 
unapproved uses.74 
Not only does the FDA endorse off-label uses, but the courts have also 
affirmed the legitimacy of these activities.  The Supreme Court has held that 
the “ ‘off-label’ usage of medical devices is an accepted and necessary 
corollary of the FDA’s mission to regulate in this area without directly 
interfering with the practice of medicine.”75  Further, “no court has held that 
a physician’s deviation from the officially approved labeling . . . is per se 	  
http://www.fda.gov/regulatoryinformation/guidances/ucm126486.htm (last visited May 
12, 2014). 
 68. Drug Maker to Pay $430 Million Fines, Civil Damages, FOOD & DRUG ADMIN. 
(Aug. 2004), http://www.fda.gov/fdac/features/2004/404_wl.html (last visited May 12, 
2014).  
 69. See 21 U.S.C. § 396 (2010). 
 70. Id. 
 71. “Off-label” and Investigational Use, supra note 67. 
 72. Id.  
 73. United States v. Evers, 453 F. Supp. 1141, 1148 (M.D. Ala. 1978). 
 74. Kim, supra note 4, at 11. 
 75. Buckman Co. v. Plaintiff’s Legal Comm., 531 U.S. 341, 349 (2001). 
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negligence.”76  While a physician’s discretion to use an approved device for 
an off-label use is not unlimited, and doctors do not “have sole and absolute 
discretion in treating their patients,”77 the ability for physicians to pursue 
off-label uses is typically quite broad. 
Although physicians may use FDA approved drugs and devices for off-
label indications, pharmaceutical manufacturers are prohibited from 
marketing or promoting these off-label uses.78  While the FDA is quite 
active in the realm of enforcement of off-label promotion, the typical 
circumstances surrounding cosmetic procedures make the ban on off-label 
promotion less effective in this particular context.79  For example, the FDA 
does not prohibit non-manufacturers from discussing the alleged benefits of 
off-label uses of approved drugs and devices, whether or not there is 
evidence to support the professed benefits, nor does it have jurisdiction to 
regulate international marketing.80 Thus, information about cosmetic uses of 
drugs and devices approved for other indications are often disseminated via 
the advertisements of physicians who engage in these off-label cosmetic 
procedures.81  Further, information about unapproved cosmetic uses may be 
available on a manufacturer’s international website or on websites 
maintained by entities that are unaffiliated with the manufacturer.82  In fact, 
media and the Internet play a large role in the American obsession with 
cosmetic surgery.  When it comes to cosmetic procedures and innovations, 
news of these treatments tend to “spread through mass marketing.  The 
Internet also spreads news and creates demand through list serves, web sites, 
chat rooms, and spam.”83  The widespread availability of information 
regarding off-label cosmetic uses of approved drugs and devices “constructs 
cosmetic surgery as an option which is not only available to everyone, but 
which bears the promise of an exalted life.”84  With a constant barrage of 
promotions and promises, the allure of cosmetic procedures becomes too 
irresistible for some to ignore. 
At the same time that the mass media extol off-label uses of drugs and 
devices for cosmetic purposes, data in the medical literature regarding the 
safety and efficacy of these off-label procedures is often relatively 
inconclusive.  Specifically, researchers and clinicians have eagerly studied 
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the effects of liquid silicone in soft tissue alteration.85  Research has led to 
the development of a method of administration known as the microdroplet 
serial puncture technique, in which small amounts of liquid silicone are 
inserted into the skin at 2-10 mm intervals.86  On the one hand, the American 
Society for Dermatologic Surgery (“ASDS”), which has issued guidelines 
regarding an array of injectable fillers, deems liquid injectable silicone 
administered by the microdroplet serial puncture technique to be a safe and 
efficacious material for permanent intra- and subdermal implantation within 
the human body.87  Physicians and researchers in this camp maintain that the 
overall cosmetic benefits of liquid silicone injections, and the fact that it 
permanently remains in the body once injected, outweigh the risks of 
migration and immune reaction.88  Notably, many clinicians prefer liquid 
silicone to other popular fillers because it can be permanently implanted 
underneath the skin, unlike collagen, fat, and Botox.89  For example, 
injectable hyaluronic acid, including products such as Restylane and 
Juvederm that are FDA-approved for injection of moderate to severe facial 
wrinkles around the nose and mouth, is only a temporary filler, as the 
substance is metabolized into carbon dioxide and water and eliminated via 
the lymphatics and eventually the liver.90 
Liquid silicone’s permanence can also be the source of its potential for 
problems, including the risk of drift, as it cannot be removed once injected.91  
Many physicians, however, maintain that the problems that plagued silicone 
in the past can now be attributed to improper technique or using an 
adulterated or impure formulation.  Using silicone in too great a volume, for 
example, can cause migration; adulterated formulations can lead to ulcers 
and redness.92  Thus, the clinicians that support the use of liquid silicone 
injections conclude that any possible issues associated with the permanence 
of liquid silicone, as compared with other injectables, can be remedied with 
proper attention to administration technique.  These researchers caution that, 
as with any filler, injection using the wrong amount, wrong material, or by 
the wrong practitioner could result in adverse outcomes, such as swelling, 	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beading, and discoloration.93  Thus, the ASDS notes that “judicious use of 
[liquid injectable silicone] requires an appreciation of normal facial anatomy 
and the changes that occur with aging and illness,” and suggests that 
practitioners who perform liquid silicone injections have completed 
residency training in a specialty where such information is taught, such as 
dermatology or plastic surgery.94 
On the other hand, some clinicians argue that liquid silicone injections 
should be absolutely contraindicated in certain circumstances, including 
injection into the breasts or horizontal facial creases, or only approached 
with an abundance of caution in other scenarios, such as in patients with 
chronic inflammatory disease or an active infection near the proposed 
injection site.95  Given the controversy surrounding liquid silicone, the 
American Society for Aesthetic Plastic Surgery (“ASAPS”) states that 
silicone injections for cosmetic purposes should not be used except in the 
context of a legitimately approved clinical trial.96  A plastic surgeon, in 
recent media coverage about the increasing use of liquid silicone as a facial 
filler, stated that liquid silicone appears to do a better job on facial lines as 
far as plastic surgeons presently know, but noted a dearth of research 
examining the long-term effects and results of these procedures up to 15 
years following injection.97 Until more concrete research is obtained, he 
urged physicians to err on the side of caution and avoid procedures 
involving liquid silicone.98  In the face of these uncertainties, physicians 
must use their best judgment to determine which FDA approved drugs or 
devices his or her patient should receive in light of the information contained 
in the product’s labeling and other available scientific data.99 
These scientific disagreements remain unsettled, despite the fact that a 
liquid silicone product known as SilSkin was granted an IDE in the early 
2000s by the FDA for clinical study of cosmetic improvement of wrinkles 
and depressions.100  SilSkin is the only liquid silicone product that has ever 
been cleared by the FDA for cosmetic clinical trials.101 Its manufacturer, 
Richard-James, Inc., was able to convince the FDA to allow clinical trials to 
proceed in part because it presented the agency with results from autopsies 	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of silicone users where material injected years earlier had not drifted.102  
Information available near the time that FDA approved this IDE indicated 
that the Phase II trials would involve 150 patients, followed for one year 
while receiving SilSkin injections on one side of the face and collagen on the 
other.103  Despite any original optimism surrounding these trials on the part 
of the manufacturer and physicians, legal issues with SilSkin’s manufacturer 
have prevented Phase III trials from commencing and producing meaningful 
results.104  In addition to these FDA-sanctioned clinical trials, a new round 
of studies involving the injection of Silikon 1000 into nasolabial folds of 
HIV patients to treat HIV-related lipoatrophy have emerged.105  Some 
physicians and researchers believe that these new trials, because they are 
more rigorously designed than previous studies, will finally “provide 
objective information regarding outcomes following the use of standardized 
small volumes of medical grade silicone.”106 
Although it remains a hypothetical question, it is important to consider the 
implications if the FDA were to approve a liquid silicone product for 
cosmetic uses.  FDA approval can trigger the requirement for manufacturers 
to engage in various forms of postmarket surveillance.  Under Section 522, 
the FDA may order the manufacturer of a Class II or Class III device to 
conduct postmarket surveillance if the failure of the device would be 
“reasonably likely to have serious adverse health consequences” or if it is 
intended to be implanted in the body for more than one year.107  Arguably, 
the possibility of silicone migration in the body after injection under the skin 
could be reasonably likely to have serious adverse health impacts.  Further, 
as a permanent filler, injected liquid silicone would be implanted in the body 
for more than one year.  Thus, FDA approval of a liquid silicone device 
could trigger helpful postmarket surveillance activities that would enhance 
monitoring of cosmetic procedures involving liquid silicone. 
FDA regulations define this type of surveillance as “the active, systematic, 
scientifically valid collection, analysis, and interpretation of data or other 
information about a marketed device.”108  Mandatory postmarket 
surveillance stemming from FDA-approval of a cosmetic indication of a 
liquid silicone device would be a great improvement to the currently weak 
system of tracking and monitoring liquid silicone injections.  Currently, the 
FDA does not track adverse events associated with cosmetic liquid silicone 	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injections.  The CDC’s Morbidity and Mortality Weekly Report 
(“MMWR”), consisting of data gathered from voluntary reporting by state 
health departments, contains only three mentions of liquid silicone 
injections.109  The report, dating back to 2007, warns of acute renal failure 
associated with silicone injections performed by unlicensed practitioners.110  
Thus, at the very least, approval of a liquid silicone product for cosmetic 
enhancement would be beneficial in remedying the dearth of available 
adverse event reporting now available. 
C. Illegal Liquid Silicone Injections 
Between 1997 and 2011, the total number of minimally invasive cosmetic 
procedures, including injectables, performed in the United States increased 
by nearly 200%.111  As detailed above, some of these cosmetic procedures 
involving the injection of liquid silicone are legal.  This occurs when 
physicians use approved liquid silicone products for unapproved off-label 
cosmetic purposes.  Unfortunately, however, the instances of illegal 
cosmetic injections of liquid silicone (or other fluids falsely claimed to be 
liquid silicone) are becoming increasingly widespread.  Illegal liquid 
silicone injections occur when individuals obtain injections at the hands of 
unlicensed professionals, or when individuals are given injections of 
adulterated or industrial-grade liquid silicone products.112  Individuals are 
primarily drawn to the cosmetic procedure black market by the promise of 
significant cost savings; while it costs roughly $5,000—7,000 to receive a 
buttocks lift or implants at a legal clinic, illegal buttocks injections may cost 
as little as $250.113  While cosmetic surgery bargain shopping may save 
money upfront, “the price to fix a mistake could cost [these individuals] 
everything,” including their health and their lives.114 
So-called “bootleg” liquid silicone is readily available, and may be 
purchased at local home improvement stores or gas stations.  Typically, this 	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adulterated liquid silicone is industrial-grade, and is often mixed with 
various impurities.115  Such impurities may include floor products, sealers, 
motor oil, and paraffin.116  This adulterated silicone fluid is then injected, 
often by individuals with no training or experience, into “cheekbones, 
eyebrow bridge, forehead, chin, lips, breasts, pectoral area, armpits, 
buttocks, penis, thighs, hands, and hips.”117  When silicone injections are 
performed in this illicit and clandestine manner, individuals who receive 
injections are often deprived of the opportunity to receive various screening 
and assessment evaluations that a licensed healthcare provider would 
typically conduct.  These assessments may include an initial consultation by 
a physician, blood testing for allergic reactions or contraindications, risk and 
benefit assessment, patient education, or social and psychological 
evaluations.118  Further, illicit liquid silicone injections too often involve the 
injection of excessive volumes of silicone, poor technique on the part of 
unskilled operators, and unhygienic conditions surrounding the procedure.119  
A rash of deaths and injuries related to illicit liquid silicone injections have 
been highlighted in the media in recent years; frequently death occurs 
following a silicone pulmonary embolism, in which injected silicone travels 
through the blood stream to the lungs.120 
Neither the Centers for Disease Control (“CDC”) or the FDA maintain 
data regarding injuries or deaths caused by illicit cosmetic injections, nor 
does the public health literature contain substantive information regarding 
the health implications of illegal liquid silicone injections.121  Research 
regarding silicone injections has been most thorough in the context of the 
transgender population.  While other population subgroups including drag 
queens, heterosexual women, and gay men currently participate in the illicit 
market for silicone injections, these injections were first adopted widely in 
the transgender community.122  Ruby Corado, one transgender woman 
profiled in a recent news article, began injecting liquid silicone into her 
buttocks, hips, and thighs in the late 1990s.123  During a beauty pageant at 
her transgender club, a man took the stage to pitch silicone injections he 
offered at a local hotel.  The man claimed he was a nurse in Cuba and 
worked with plastic surgeons, and Corado became hooked on the 	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procedures.  Nearly two decades later, however, Corado told reporters that 
her “silicone hips have migrated to her thighs and her once-juicy booty is 
hard and sensitive to the touch. Her immune system is weak, but she knows 
her symptoms could be much worse.”124  Such hotel room procedures have 
been common in the transgender community, as has the phenomenon of 
dangerous “pumping parties.”125  At a typical pumping party, groups of 
transgender individuals receive silicone injections from an unlicensed, 
untrained person using non-medical silicone.  These parties may occur at a 
beauty parlor, at a private home, or even in a warehouse.  According to one 
doctor who specializes in transgender health services, economically 
disadvantaged and vulnerable transgendered individuals are particularly 
willing to forego safety costs in the pursuit of beauty because being shapely 
and beautiful is “a self-esteem builder for people who are feeling rejected by 
their families and communities.”126  Given the fact that illicit liquid silicone 
injections and pumping parties have been popular within the transgender 
community for quite some time, some data regarding the prevalence of these 
practices among transgender individuals has been amassed.  Research has 
found  “illicit injection silicone rates among transwomen to be 25% in 
Washington, DC; 30% in New York City and Chicago; and 33% in Los 
Angeles.”127  Moreover, the National Coalition for LGBT Health has 
confirmed this startling prevalence, reporting that the injection of industrial 
silicone is so widespread among transpersons that it is one of 13 high 
priority health issues affecting the population.128 
In recent years, however, pumping parties have gained popularity amongst 
other population subgroups outside of the transgender community.  For 
example, many young, African-American women are now pursuing silicone 
injections to amplify their curves.  As one news article put it: “[h]aving once 
shied away from and even denounced plastic surgery, black women are 
embracing it now more than ever.”129  Pop culture has fueled the desire for a 
fuller behind, and society has gone from accepting curves to obsessing over 
large bottoms.130  In fact, in 2011, racial and ethnic minorities received 21% 
of all cosmetic procedures: Hispanics, 8%; African-Americans, 7%; Asians, 
5%; and other non-Caucasians, 1%. 131  In addition to the growing popularity 
among African-American women, Hispanic women are also increasingly 
turning to illicit liquid silicone injections. 	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Indeed, South Florida “has become the nation’s capital of black market 
beauty treatments.”132  Many illegal beauty treatments in this region are 
offered by immigrant practitioners who live in the state, or by foreign health 
care practitioners who fly to Florida to treat clients.133  Some have noted that 
“Miami offers perfect-storm conditions for cosmetic crime, [as] it’s a nexus 
of vanity, greed, corruption, warm weather, beautiful men and women 
walking around all the time wearing as little clothing as possible and 
unsophisticated immigrants trying to compete with them.”134  The social 
fabric of Miami and its large immigrant populations can help foster 
underground cosmetic procedure providers.  Women within these tightly 
knit immigrant communities may be more likely to trust the 
recommendations of friends and family who have been treated by various 
black market practitioners.135  For example, one Florida woman named 
Angelina McCabe used local beauty salons to network and get referrals for 
her silicone lip injection business.  When McCabe was ultimately reported 
by a victim, it came to light that some clients had contracted herpes from her 
unsanitary syringes, which were found in her medical bag used and covered 
with dog hair.136 
IV. REGULATION OF AND ENFORCEMENT AGAINST ILLICIT LIQUID SILICONE 
INJECTIONS 
Given the increasing prevalence of illicit liquid silicone injections, as well 
as the significant health risks associated with these procedures, it is critical 
that both the federal government and state and local governments actively 
enforce laws and regulations designed to curb such practices.  At the federal 
level, this enforcement jurisdiction rests primarily with the FDA.  Although 
physicians may lawfully use an approved liquid silicone product for an off-
label cosmetic use, no person may administer unapproved, adulterated liquid 
silicone devices in any manner.  The 1976 Medical Device Amendments to 
the FDCA established three regulatory classes for medical devices based on 
risk and the degree of control necessary to ensure safety and effectiveness.  
Class III devices are the most stringently regulated, and Section 515 of the 
FDCA requires all Class III medical devices to obtain an approved PMA.137  
A Class III device that fails to meet PMA requirements is considered to be 	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adulterated under Section 501(f) of the act and cannot be marketed.138  
Silikon 1000 and Adatosil 5000, the two FDA-approved silicone oil 
products, are Class III devices that submitted successful PMA applications 
to the FDA in 1997 and 1994, respectively.139 
The FDA continues to regulate medical devices once they are successfully 
approved for marketing in interstate commerce by controlling the contents of 
the product’s labeling.  First, the FDA demands that the label of a medical 
device must not be false or misleading in any particular.140  Therefore, if a 
manufacturer falsely held out a silicone oil product for sale to physicians as 
Silikon 1000 or Adatosil 5000, the product would be misbranded under the 
FDCA.  Second, a medical device’s label must provide adequate directions 
for use.141  The label must therefore include directions related to the FDA-
approved use of Silikon 1000 and Adatosil 5000 for the treatment of retinal 
detachment.  Failure to include these adequate directions for use on a label 
misbrands the device under the FDCA.142  Furthermore, any addition to the 
device’s labeling that would suggest that the liquid silicone product was 
FDA-approved for a cosmetic or other indication would cause the device to 
be adulterated under the FDCA.  This is because Section 501(f)(1)(B) of the 
Act, requiring pre-market approval for Class III devices, considers claims 
that exceed the scope of a previously FDA-approved indication to adulterate 
the device.143 
“Federal regulation of medical products is grounded in the introduction of 
devices in interstate commerce for commercial distribution, not use by 
physicians.”144 In regards to medical devices, “the doctrine implies that a 
licensed physician may use any legally marketed device for any indication 
that he or she feels is appropriate.”145  This concept forms the basis for the 
“practice of medicine” doctrine, which maintains that FDA lacks authority 
under the FDCA to regulate the patient treatment decisions of licensed 	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physicians.146  Thus, federal regulatory efforts are directed primarily at 
device marketing by manufacturers, not device use by physicians.147  It is 
quite possible, therefore, that a state-licensed physician may enjoy wide 
latitude in treatment use of a medical device that the physician himself or 
herself has modified, even if the same modification of an FDA-approved 
device would be sufficient to trigger 501(f)(1)(B) of the Act where a 
manufacturer made such changes.148 
Therefore, it falls entirely on the state to appropriately regulate the 
practice of medicine.  The Supreme Court has long recognized that the 
state’s police powers justify their regulation of the practice of medicine and 
allow the state to license health care professionals.149  Thus, states maintain 
statutes that regulate various fields of the medical profession and define the 
scope of practice in which health practitioners may engage.150  These 
statutes typically define the authorized practice of medicine and also define 
and punish unauthorized practice.151  Generally, the unauthorized practice of 
medicine occurs in one of two scenarios.152  First, when a person without a 
medical license performs activities that fall under the definition of the 
practice of medicine or holds himself or herself out as a licensee.153  Second, 
when an otherwise licensed practitioner performs activities outside the scope 
of his or her particular medical field.154  Beyond state medical board 
oversight, state law also regulates the practice of medicine through private 
suits for malpractice.155  Theoretically, “physicians who practice in a manner 
that is unsafe or ineffective can face disciplinary action and civil liability.  
But, in reality, state medical boards infrequently discipline physicians for 
improper practice.”156  In addition, it has been found that the threat of 
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potential malpractice suits also does not seem to deter the proliferation of 
questionable medical services.157 
While “state statutory definitions [of the practice of medicine] vary 
tremendously, most of them include diagnosis, prescribing, and surgical 
interventions among the central attributes of medical practice.”158  In 
Florida, Section 456.065 of Chapter 456 of the Florida Statutes regulates the 
unlicensed practice of a health care profession.159 The statute prohibits “the 
unlicensed practice of a health care profession or the performance or 
delivery of medical or health care services to patients in this state without a 
valid, active license to practice that profession, regardless of the means of 
the performance or delivery of such services.”160  Penalties for the 
unlicensed practice of a health care profession in Florida include: (1) 
Issuance of a cease and desist letter when the Department has probable cause 
to believe an unlicensed person has violated the statute or that a person has 
aided and abetted the unlicensed practice of a profession by employing an 
unlicensed person; (2) An administrative penalty not to exceed $5,000 per 
incident; (3) A civil penalty of no less than $500 and no more than $5,000 
for each offense; and (4) Criminal penalties.161 
While the existence of state statutory provisions defining the unlicensed 
practice of medicine is important, it is critical that these laws be effectively 
and efficiently enforced in order to deter and punish individuals who seek to 
perform unlawful cosmetic injections.  “Florida has a dedicated investigative 
arm for unlicensed activity.”162 The Division of Medical Quality Assurance 
(“MQA”) regulates 37 types of facilities and 43 health care professions.163  
The MQA serves a variety of functions, including credentialing licensing 
applicants, inspecting facilities, and decreasing unlicensed activity. 164 The 
MQA also maintains a separate unlicensed activity unit (“ULA”); in 
cooperation with law enforcement and state attorney generals, the ULA 
seeks to prosecute unlicensed practitioners.165  In order to identify these bad 
actors, all complaints are routed centrally through the Florida Department of 
Health.166  If, upon preliminary review, the complaint is deemed legally 
sufficient, it is forwarded to a ULA investigator located in close geographic 	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proximity to the complaint location.167  Local ULA investigators undertake 
activities such as interviewing the complainant and witnesses, gathering 
documents, and conducting surveillance in order to determine whether or not 
the allegations contained in the complaint are supported.168  These ULA 
investigations are designed to develop the probable cause law enforcement 
entities require to file criminal charges.  Fees contributed by licensees fund 
the ULA; all licensees must pay a $5 special fee for both initial licensing and 
each subsequent renewal.169  According to the program’s fourth quarter 2012 
Quarterly Performance Report, 99 complaints were filed with the ULA, 76 
investigations were completed, 52 cases were referred to law enforcement, 
and 16 arrests resulted from ULA investigations.170 
California uses a similar vertical prosecution model to enforce its laws 
related to the unlicensed practice of medicine.171  First, consumers file a 
complaint with the Medical Board of California.172  This complaint is 
directed to the Board’s Central Complaint Unit (“CCU”).  Then, a Deputy 
Attorney General and the Complaint Unit Analyst make a determination 
regarding whether or not immediate investigation or some other government 
action is warranted by the complaint.173 If an investigation is warranted, the 
CCU forwards relevant information to the District Office in closest 
proximity to where the alleged acts of unlicensed practice occurred.174  At 
this stage, the case is assigned to an investigator and a Deputy Attorney 
General.175  This team will work together on the case until it is either: (1) 
closed; (2) referred for disciplinary action; or (3) referred for other action, 
including a criminal prosecution.176  If a criminal prosecution is sought, the 
team forwards the case file to a district attorney in the relevant 
jurisdiction.177 
In addition to unlicensed practice statutes, some states include specific 
language regarding the administration of cosmetic injections and other 
cosmetic procedures in laws, regulations, and policies that delineate the 
scope of practice of various health care professions.178  In particular, many 	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states have issued guidelines regarding which medical professionals are 
permitted to inject patients with Botox and other dermal fillers.179 Although 
these provisions do not explicitly mention liquid silicone injections, states 
that have restricted cosmetic injections of dermal fillers in some manner 
include: Alabama, California, Colorado, Florida, Georgia, Kentucky, 
Maryland, Mississippi, Missouri, New Jersey, New Mexico, Ohio, 
Oklahoma, Oregon, Rhode Island, South Carolina, and South Dakota.180  
These laws and policies, however, vary widely from state to state.181 
Alabama, New Jersey, and South Carolina, for example, restrict cosmetic 
injections to licensed physicians.182 In South Carolina, however, this 
restriction is merely embodied in a policy issued by the state’s Board of 
Medical Examiners; as such, disciplinary action may be the only likely result 
of its violation.183 The policy, issued during the Board’s 2002 board 
meeting, states that “the revision, destruction, or other structural alteration of 
human tissue using an injection of drugs is surgery.  Botox injections should 
be performed only by individuals licensed to practice medicine and perform 
surgical services.”184 
Many of the other states listed simply provide guidelines for procedures 
that must or should be followed when a physician delegates the 
administration of dermal fillers to nurses, physician’s assistants, or other 
allied health professionals.  In Maryland, for example, a cosmetic medical 
procedure can be delegated to a physician’s assistant or to another health 
care professional licensed under the Maryland code whose licensing board 
states that such procedure falls within the scope of that licensee’s practice.185  
Finally, the status of some state laws and policies in this area are conflicting 
or confused.  In Colorado, for example, a broad regulation provides 
restrictions and guidance related to delegation of medical aesthetic services 
such as Botox and other injections,186 but information available from the 
state’s Board of Barbering and Cosmetology states that “[c]ollagen, silicone, 	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or Botox injections are invasive procedures and may only be performed by 
licensed physicians.”187 
Relatively few states currently maintain laws specifically banning 
cosmetic uses of liquid silicone.  In California, it is a misdemeanor to 
knowingly prescribe, dispense, administer, or furnish any liquid silicone 
substance for the purpose of injection into a human breast or mammary.188  
Notably, the breadth of this statute is restricted in two primary ways: first, 
this law specifies an intent requirement of “knowledge,” and second, only 
injection of liquid silicone into the breast or mammary is specifically 
outlawed.  In Nevada, with the exception of use for the treatment of retinal 
detachment, it is unlawful for a person to inject any liquid silicone substance 
into the body or to sell any liquid silicone substance for the purpose of 
injection into the human body.  Violation of this provision is a category D 
felony.  This law is much stricter than the California statute.  The plain 
language of the Nevada statute implies that it is unlawful for even a 
physician to pursue cosmetic injections of liquid silicone as an off-label 
use.189  While the California and Nevada statutes are the only state 
regulations currently in force, Rhode Island has proposed a law that would 
function in a similar manner to Nevada’s law.  The proposed statute states 
that medical licenses may be denied or revoked if a health professional 
“[performs, assists, or advises] in the injection of any liquid silicone 
substance into the human body.”190  While it is promising that a few state 
legislatures have focused specifically on the dangers of cosmetic liquid 
silicone injections, it is simultaneously disheartening that these statutes are 
in effect in so few jurisdictions. 
V. THE WAY FORWARD: THE MOST PROMISING LEGAL TACTICS FOR 
CONTROLLING LIQUID SILICONE INJECTIONS 
The rampant use of liquid silicone in cosmetic procedures, despite an 
overwhelming lack of scientific data and information demonstrating safety 
and concerns regarding serious health risks, triggers cause for concern and 
increased attention to the implications of its widespread use.  In addition, the 
growing prevalence of unlicensed practitioners hawking cheap but unsafe, 
even lethal, illicit liquid silicone injections provides a reason to focus not 
only on its used by licensed professionals, but also on the market for liquid 
silicone in general.  This section outlines how the federal government could 
address these issues, but ultimately explains that federal regulation in this 
area has traditionally been weak, and will not likely be augmented to cover 	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liquid silicone.  Thus, in place of enhanced federal enforcement, this section 
concludes with state-level regulatory and enforcement tactics aimed at both 
licensed healthcare professionals and unlicensed practitioners. 
A. Federal Enforcement Is Unreliable and Likely to Be Weak or Non-
Existent 
As discussed in parts II and III supra, FDA enforcement against off-label 
cosmetic uses of liquid silicone has historically been weak.  Although FDA 
has never approved a liquid silicone device for cosmetic uses, the agency 
does not generally interfere with off-label procedures involving these 
devices.  While it is true that the FDA did enter consent decrees of 
permanent injunction against physicians such as Dr. Norman Orentreich, 
who violated liquid silicone IDE protocols in the early 1990s, these federal 
enforcement efforts were relatively weak.191  Further, these injunctions were 
instigated because physicians were purposely violating IDE protocols 
specifying that liquid silicone trials were not to involve cosmetic uses.192  
Thus, there is reason to assume that the FDA would be even more hesitant to 
pursue action against physicians improperly using a device such as SilSkin 
in a clinical trial, as that product did receive an IDE for cosmetic testing. 
Despite the FDA’s acceptance of off-label prescribing of approved drugs, 
it is theoretically possible that Congress could carve out an exception for 
liquid silicone.  Congress could enact a statute that directs FDA to curtail 
off-label cosmetic uses of approved liquid silicone by physicians.  It is 
difficult to imagine that this sort of legislation would be politically feasible; 
the medical community is a powerful constituency in any state, and it 
typically decries FDA regulation of the practice of medicine.193  It could be 
argued, however, that, when it comes to off-label medical uses of silicone 
fluid specifically, the informal moral and social controls that serve to protect 
patients do not always work.  Due to a convergence of factors including 
societal pressure to attain beauty standards, the lucrative nature of the 
cosmetic surgery and procedures industry, and the still largely unknown 	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long-term safety and efficacy profile of injectable liquid silicone, a stronger 
regulatory stance is needed for this particular device.  Indeed, this sort of 
action would not be entirely unprecedented.  Congress has expressly 
prohibited all off-label use for one drug, human growth hormone (“HGH”).  
Section 3303(e)(1) of the FDCA makes it a criminal offense for a physician 
to distribute HGH for any use other than the FDA-approved labeled use.194 
B. State-Level Solutions Can Produce Immediate Results 
As noted above, there are significant barriers standing in the way of 
effective federal enforcement against off-label cosmetic procedures 
involving liquid silicone.  As such, states should be encouraged to take the 
lead in regulating the off-label and illicit cosmetic uses of liquid silicone.  
The following section outlines state-level enforcement tactics geared 
towards both physicians and unauthorized practitioners that promise to be 
more immediately feasible and practicable than federal solutions. 
1. State-Level Enforcement Tactics Targeting Physicians and the 
Healthcare Community 
One of the most promising avenues for state-level efforts to reduce the 
number of dangerous cosmetic procedures involving liquid silicone 
performed is encouraging state medical boards to revisit and amend their 
practice of medicine and scope of practice laws.  While the unlicensed 
practice of medicine tends to attract more negative publicity and media 
attention, the fact that nearly all U.S. jurisdictions permit any physician with 
a medical degree and license to perform cosmetic procedures, regardless of 
his or her level of formal or specialized training in any relevant field, should 
be deeply troubling, as well.195  Although approximately 80 percent of 
licensed physicians receive specialty certification from one of 24 boards 
approved by the American Board of Medical Specialties, a process requiring 
at least three years of residency in the chosen concentration area and 
extensive oral and written exams, there are no laws in the United States that 
require doctors to practice only within the specialty fields in which they 
were trained.196  Further, only Texas, California, Louisiana, and Florida 
require physicians, in their advertising, to be specific about which specialty 
board certifications they have; elsewhere, the vague accolade, “board-	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certified,” suffices.197  Because doctors do not have to report to any 
oversight authority that they are practicing outside their specialty, there are 
no figures indicating exactly how many physicians are doing so.  
Nevertheless, media reports of patients being seriously injured by cosmetic 
surgery performed by unqualified doctors abound, indicating that the 
unregulated nature of cosmetic surgery is cause for concern.198 
Some physicians who aspire to be cosmetic surgeons attend weekend-long 
continuing medical education courses, where they learn to perform filler 
injections and liposuction by physicians who themselves are not certified by 
the American Board of Plastic Surgery.199  Often, these newly-minted 
cosmetic surgeons claim certification by Boards that are not endorsed by the 
American Board of Medical Specialties, and which have lower standards and 
are far less rigorous.200 
It is precisely these issues that spurred Puerto Rico’s Board of Medical 
Examiners to enact the nation’s first regulation limiting the practice of 
cosmetic medicine to particular classes of medical specialists in 2005.201  
The plaintiff who challenged this regulation was a physician with board 
certification in obstetrics and gynecology that, while practicing, shifted his 
focus to performing liposuctions and breast implantations almost 
exclusively.202  The Board had come to recognize that this “plaintiff’s 
odyssey was not unique,” and noticed that “the majority of professionals that 
market[ed] their services as ‘aesthetic medicine’ [were], in reality, general 
physicians that [had] no formal training . . . in the skills that are purportedly 
offered to the public.”203  Thus, the Board deemed it the “illegal practice of 
medicine [when] any person . . . advertises, practices or purports to practice 
the procedures that fall under the competence of dermatologists or plastic 
surgeons without possessing the certification in the corresponding 
specialty.”204  The First Circuit Court of Appeals upheld this regulation in 
2011.205  More states should follow the lead of Puerto Rico and limit the 	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practice of cosmetic surgery to physicians who have been certified by the 
American Board of Plastic Surgery or the American Board of Dermatology.  
These sorts of restrictions may be a necessary step, as there is some evidence 
that, given how lucrative aesthetic medicine can be for practitioners, doctors 
who provide these types of services may be less likely to self-regulate in a 
manner that is sufficiently stringent.206 
States can also make enhanced efforts to restrict off-label cosmetic uses of 
liquid silicone in a manner the FDA cannot or will not, given its 
commitment to giving physicians a wide berth when it comes to off-label 
prescribing or use of FDA-approved drugs.  As discussed in part IV supra, 
some states have enacted statutes that make it a criminal offense to inject 
liquid silicone into a person’s body.  Specifically, the plain language of 
Nevada’s law prohibits all medical uses, cosmetic or otherwise, for liquid 
silicone products beyond its narrow approved indication for treating retinal 
detachment.207  More states should consider adopting similar statutes, which 
would deter cosmetic uses for liquid silicone by licensed physicians and 
unlicensed practitioners alike. 
2. State-Level Enforcement Tactics Targeting Unlicensed 
Practitioners and Illicit Uses for Liquid Silicone Products 
States may be hesitant to interfere with the practice of medicine and a 
physician’s reasoned medical discretion in using approved liquid silicone 
products for off-label uses.  If this is the case, states can focus primarily on 
eradicating illegal and black market uses of liquid silicone and silicone oil.  
For example, states can enact laws that regulate the sale of commercial grade 
silicone, often used in illicit silicone injections by unlicensed practitioners.  
A parallel area of state legislation that states can use as a model for such 
laws can be imported from the regulation of the dispensation and distribution 
of various legal substances that can be used illicitly as inhalants.  For 
example, Ohio Law prohibits dispensing nitrous oxide to any person under 
the age of 21, or to a person over the age of 21 if the person who dispenses 
the substance knows or has reason to believe that person over the age of 21 
will use the nitrous oxide as an intoxicant.208  The law also requires those 
who dispense or distribute nitrous oxide cartridges to comply with record-
keeping and labeling requirements.209  Anyone who dispenses nitrous oxide 
must record each transaction on a card, which must include the purchaser’s 
signature and residence address, as well as information stating that the 
nitrous oxide cartridges are to be used only for purposes of preparing food, 	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and that inhalation of nitrous oxide can have dangerous health effects.210   
Further, the law requires each cartridge of nitrous oxide dispensed or 
distributed within the state to bear the following warning label: “Nitrous 
oxide cartridges are to be used only for purposes of preparing food. Nitrous 
oxide cartridges may not be sold to persons under age twenty-one. Do not 
inhale contents. Misuse can be dangerous to your health.”211  Similarly, 
states could apply these types of regulations to liquid silicone products, 
making it more difficult to purchase these products for illicit uses, and 
making it easier for the state to track those who do purchase the product. 
Another key area for state action targeting illicit uses of liquid silicone 
products by unlicensed practitioners rests with state attorneys general 
offices.  As discussed in section IV, supra, Florida’s ULA has achieved a 
strong track record in deterring and punishing individuals who offer and 
conduct dangerous cosmetic procedures within the state.212  There are 
several avenues that can be used to encourage a state attorneys general office 
to focus enforcement activities in a certain area, such as illicit injections of 
liquid silicone products.  First, licensed practitioner groups, such as state 
medical associations, could lobby the state to take increased steps to root out 
bad actors from within the industry that provide off-label cosmetic injections 
of liquid silicone for profits, despite a lack of scientific knowledge regarding 
the long-term effects and health consequences of these procedures.  In this 
way, the state can serve as enforcement support in an industry’s attempt to 
police itself.  Second, state attorney general offices can be alerted to the need 
for increased attention to this issue through consumer complaints.  Citizens 
who have been the victim of dangerous cosmetic procedures involving liquid 
silicone should be encouraged to report their ordeals to the state; awareness 
campaigns could help decrease the embarrassment or stigma associated with 
doing so.  Finally, because states often obtain their legislative and 
enforcement priorities from cases or issues on the horizon in other states, 
and often learn of national issues from contacts at meetings of organizations 
like the National Association of Attorneys General (“NAAG”), those 
interested in promoting more widespread enforcement efforts against illicit 
liquid silicone injections can attempt to spread awareness of the dangers of 
these procedures by giving seminars at the meetings and conferences of 
these associations.213  If states do begin to embark on greater enforcement 	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efforts in this area, it could be helpful for neighboring jurisdictions to band 
together and create a reporting network or database, which would store data 
and information related to the results of these various tasks forces and 
investigatory efforts.  Given enough traction and progress, the information 
contained in this database could help public health stakeholders build a case 
for eventual federal regulation or oversight to curb a major nationwide 
health issue. 
VI. CONCLUSION 
Although the FDA has historically focused some regulatory scrutiny on 
the cosmetic uses of liquid silicone products, the scope of such efforts has 
been limited, and has not resulted in effective deterrence.  While the science 
regarding the safety and long-term effects of cosmetic liquid silicone 
injections remains inconclusive, and the illicit uses of liquid silicone on 
vulnerable populations by unlicensed practitioners grows increasingly more 
prevalent, it is important to remain cautious, and to keep close watch on 
these procedures.  It is critical, therefore, that states take up the federal slack 
in this area.  States can accomplish this by restricting the use and sale of 
liquid silicone products by physicians and unlicensed practitioners alike, and 
also by prioritizing enforcement activities on deterring illicit liquid silicone 
injections, which are arguably the most lethal, and most hidden, practices 
involving this substance. 
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